Leo Pharma Eyes $800 Million Deal Push as IPO Plans Advance

Leo Pharma is actively seeking more acquisition targets, with as much as 5 billion kroner ($800 million) to spend on dealmaking as it positions itself for an initial public offering, according to its top management.

The Danish drugmaker, which specializes in skin conditions, has “clear support and firepower to complete more deals,” Chief Executive Officer Christophe Bourdon said in an interview. This follows its purchase of gene therapy company Replay last week, its third acquisition in 16 months.